Incysus Therapeutics Inc. announced the appointment of Peter C. Brandt to the company’s Board of Directors. Mr. Brandt has over 30 years of operational and Board experience in the biopharmaceuticabl industry. Most recently, he was the President and Chief Executive Officer of Noven Pharmaceuticals, through its acquisition. Prior to leading Noven, Mr. Brandt spent 28 years at Pfizer, most recently as President, U.S. Pharmaceuticals Operations. In that position, Mr. Brandt helped deliver revenue and earnings growth while engineering major change within the organization. Prior to that position, Mr. Brandt led the Latin American Pharmaceuticals Operations, as well as the Worldwide Pharmaceuticals functions of Finance, Information Technology, Planning and Business Development. He also oversaw the operations of Pfizer’s care management subsidiary, Pfizer Healthcare Solutions. Currently, Mr. Brandt is the Chairman of Rexahn Pharmaceuticals and serves as a Trustee of The Population Council. He has also served on the Boards of Auxilium Pharmaceuticals (acquired by Endo Pharmaceuticals), ePocrates (acquired by AthenaHealth), and Noven Pharmaceuticals (acquired by Hisamitsu Pharmaceutical Co. Inc.). Mr. Brandt holds a BA from the University of Connecticut and an MBA from the Columbia School of Business.